甲氨蝶呤联合米非司酮治疗异位妊娠疗效分析

Efficacy of treating ectopic pregnancy by Methoterxate combined with Mifepristone

目的观察并探讨甲氨蝶呤联合米非司酮治疗异位妊娠(EP)的临床疗效。方法选取西安医学院第一附属医院收治的异位妊娠患者109例,随机分为两组,其中对照组53例,给予米非司酮口服治疗;治疗组56例,在对照组用药基础上加用甲氨蝶呤肌内注射治疗,3d疗程结束后对比评价两组的临床疗效及不良反应。结果治疗组患者的治愈率为89.3%,对照组为66.0%,治疗组治愈率显著高于对照组(x^2=8.571,P<0.05)。治疗3d后,治疗组血β-hCG和盆腔包块直径均明显低于对照组(t值分别为9.205、4.546,均P<0.05)。治疗组不良反应发生率(5.36%)与对照组(7.55%)相比,差异无统计学意义(x^2=0.217,P>0.05)。结论甲氨蝶呤联合米非司酮治疗异位妊娠的疗效显著,不良反应少,值得在临床推广。

Objective To explore the clinical efficacy of treating ectopic pregnancy （EP） by Methoterxate combined with Mifepri.stone. Methods Totally 109 patients with EP were randomly divided into control group and treatment group. The control group with 53 cases was given Mifepristone, while the treatment group of 56 cases was given Methotrexate combined with Mifepristone. At the end of treatment （3- day course）, clinical efficacy and adverse reactions were compared between two groups. Results The cure rate of the treatment group （89.3%） was significantly higher than the control group （66.0%） （χ^2 = 8. 571, P 〈 0.05 ）. After treatment for 3 days, the level of blood 13-hCG and the size of pelvic mass of the treatment group were significantly lower and smaller than those in the control group （ t value was 9. 205 and 4. 546, respectively, both P 〈 0.05 ）. The incidence of adverse reactions was not significantly different between the treatment group （5.36%） and the control group （7.55 % ） （χ^2 = 0. 217, P 〉 0.05 ）. Conclusion The clinical efficacy of Methoterxate combined with Mifepristone is significant in treating EP with less adverse reactions, and it＇ s worthy of clinical application.